T cells

[Daiichi Sankyo Company, Limited] Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T cell leukemia/lymphoma.

[Clinical Cancer Research] Researchers performed targeted next-generation sequencing, immunohistochemistry for MYC, BCL2, and FN1, and fluorescent multiplex immunohistochemistry for microenvironmental markers in a large cohort of diffuse large B cell lymphoma.

[Blood Advances] The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T cell engager molecule, for treatment of pediatric relapsed/refractory B cell precursor acute lymphoblastic leukemia were examined in an open-label, single-arm, expanded access study (RIALTO).

[Molecular Cancer Research] The authors showed that in T-ALL cells, growth factor independence-1 (GFI1) and IKAROS were transcriptional partners that co-occupied regulatory regions of hallmark T cell development genes. Transcriptional profiling revealed a subset of genes directly transactivated through the GFI1-IKAROS partnership.

[Trends in Immunology] Scientists explore potential tumor microenvironment metabolic determinants that might constitute candidate targets for cancer immunotherapies, ideally leading to future strategies for reprogramming tumor metabolism to potentiate anticancer T cell functions.

[Nature Communications] Scientists described how heterocellular Oncostatin M (OSM) - Oncostatin M Receptor (OSMR) signaling reprograms fibroblasts, regulates tumor growth and metastasis.